The FIGO staging system is an integral part of the therapeutic and treatment process in female genital tumors. It cements the knowledge gained to date to plan patient treatment prognosis and the course of the disease and compare treatment outcomes between centers in the most individualized yet systematic way. In response to these assumptions, the FIGO Committee on Gynaecological Oncology updated the endometrial cancer staging classification in June 2023. The new endometrial cancer staging classification includes multiple clinicopathological prognostic factors and molecular findings for the first time. In this review, we summarize the differences between the new and the old FIGO classification and comment on its everyday real-world application.